ArticleISRN gastroenterology2012
Transcatheter arterial chemoembolization: history for more than 30 years.
Article in ISRN gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- Impact of microvascular invasion risk on tumor progression of hepatocellular carcinoma after conventional transarterial chemoembolization.The oncologist · 2025Article
- Cardio-Oncoimmunology: Cardiac Toxicity, Cardiovascular Hypersensitivity, and Kounis Syndrome.Life (Basel, Switzerland) · 2024Article
- Applications of image-guided locoregional transarterial chemotherapy in patients with inoperable colorectal cancer: a review.Frontiers in oncology · 2024Review
- Article
- Review
- Review
- Review of cancer therapies for the perioperative physician.Perioperative medicine (London, England) · 2023Review
- MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.BMC medical imaging · 2023Article
- Interventional nanotheranostics in hepatocellular carcinoma.Nanotheranostics · 2023Review
- Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.Cureus · 2022Review
- The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases.Cancers · 2022Review
- The Expression and Prognostic Value of Cancer Stem Cell Markers, NRF2, and Its Target Genes in TAE/TACE-Treated Hepatocellular Carcinoma.Medicina (Kaunas, Lithuania) · 2022Article
- Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.Cancers · 2021Review
- Combination therapy with percutaneous osteoplasty and transcatheter arterial chemoembolization for the treatment of pelvic bone metastases: preliminary report.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Synthesis, characterization, and imaging of radiopaque bismuth beads for image-guided transarterial embolization.Scientific reports · 2021Article
- A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents.International journal of medical sciences · 2021Review
- Value of Dyna CT in guiding embolization during transarterial uterine artery embolization of fibroids.Experimental and therapeutic medicine · 2020Article
- HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α.Oncogene · 2020Article
- Intermittent hypoxia alleviates increased VEGF and pro-angiogenic potential in liver cancer cells.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter arterial chemoembolization (TACE) is a minimally invasive technique to treat liver tumors, particularly hepatocellular carcinoma (HCC). TACE was used in early times to treat liver tumor patients with emergencies caused by symptomatic humoral hypercalcemia and develops gradually from the procedures of diagnostic angiography and transcatheter injection of agents and is in particular performed in the treatment of HCC. Since the beginning of this century, TACE has been used extensively in the palliative treatment of unresectable HCC. In recent years, it is indicated in selected patients with early-stage HCC. This review introduces the evolution of TACE for more than 30 years, its role in comprehensive treatment of HCC, the tendency of its refinement in future, and the combination use of TACE with other local ablative methods for the curative result of HCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.